Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/21317
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPolyzos, N. P.en
dc.contributor.authorMauri, D.en
dc.contributor.authorIoannidis, J. P.en
dc.date.accessioned2015-11-24T19:14:28Z-
dc.date.available2015-11-24T19:14:28Z-
dc.identifier.issn1932-6203-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/21317-
dc.rightsDefault Licence-
dc.subject*Evaluation Studies as Topicen
dc.subjectFemaleen
dc.subjectGenital Neoplasms, Female/*drug therapy/*pathologyen
dc.subjectHumansen
dc.subjectNeoplasm Stagingen
dc.subject*Practice Guidelines as Topicen
dc.subject*Societies, Medicalen
dc.subjectTreatment Outcomeen
dc.titleGuidelines on chemotherapy in advanced stage gynecological malignancies: an evaluation of 224 professional societies and organizationsen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.primary10.1371/journal.pone.0020106-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/21611154-
heal.identifier.secondaryhttp://www.plosone.org/article/fetchObjectAttachment.action?uri=info%3Adoi%2F10.1371%2Fjournal.pone.0020106&representation=PDF-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2011-
heal.abstractBACKGROUND: Clinical practice guidelines are important for guiding practice, but it is unclear if they are commensurate with the available evidence. METHODS: We examined guidelines produced by cancer and gynecological societies and organizations and evaluated their coverage of and stance towards chemotherapy for advanced stage disease among 4 gynecological malignancies (breast, ovarian, cervical, endometrial cancer) where the evidence for the use of chemotherapy is very different (substantial and conclusive for breast and ovarian cancer, limited and suggesting no major benefit for cervical and endometrial cancer). Eligible societies and organizations were identified through systematic internet searches (last update June 2009). Pertinent websites were scrutinized for presence of clinical practice guidelines, and relative guidelines were analyzed. RESULTS: Among 224 identified eligible societies and organizations, 69 (31%) provided any sort of guidelines, while recommendations for chemotherapy on advanced stage gynecological malignancies were available in 20 of them. Only 14 had developed their own guideline, and only 5 had developed guidelines for all 4 malignancies. Use of levels of evidence and grades of recommendations, and aspects of the production, implementation, and timeliness of the guidelines did not differ significantly across malignancies. Guidelines on breast and ovarian cancer utilized significantly more randomized trials and meta-analyses. Guidelines differed across malignancies on their coverage of disease-free survival (p = 0.033), response rates (p = 0.024), symptoms relief (p = 0.005), quality of life (p = 0.001) and toxicity (p = 0.039), with breast and ovarian cancer guidelines typically covering more frequently these outcomes. All guidelines explicitly or implicitly endorsed the use of chemotherapy. CONCLUSIONS: Clinical practice guidelines are provided by the minority of professional societies and organizations. Available guidelines tend to recommend chemotherapy even for diseases where the effect of chemotherapy is controversial and recommendations are based on scant evidence.en
heal.journalNamePLoS Oneen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Files in This Item:
File Description SizeFormat 
Polyzos-2011-Guidelines on chemot.pdf93.08 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons